Zacks Investment Research upgraded shares of DIASORIN SPA EUR1 (NASDAQ:DSRLF) from a hold rating to a buy rating in a research note published on Friday morning. The brokerage currently has $99.00 target price on the stock.
According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “
DIASORIN SPA EUR1 (DSRLF) opened at 88.70 on Friday. The company has a market capitalization of $4.86 billion and a price-to-earnings ratio of 32.53. The stock has a 50 day moving average price of $84.85 and a 200 day moving average price of $84.20. DIASORIN SPA EUR1 has a 12-month low of $54.50 and a 12-month high of $88.78.
ILLEGAL ACTIVITY NOTICE: “DIASORIN SPA EUR1 (DSRLF) Lifted to Buy at Zacks Investment Research” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/10/09/diasorin-spa-eur1-dsrlf-lifted-to-buy-at-zacks-investment-research.html.